Vimarsana
Biggest News Aggregation in the World

Page 38 - Looking Statement News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Looking Statement. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Looking Statement Today - Breaking & Trending Today

European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy - Vimarsana News

European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy

Published: October 16, 2023

RAHWAY, N.J.--(BUSINESS WIRE)--Oct 16, 2023--

Source: valdostadailytimes.com
Related Topics:
United StatesSolange PetersGregory LubinieckiPeter DannenbaumDamini ChokshiJulie CunninghamStatement Of Merck Co IncMerck Research LaboratoriesMerck Co IncEuropean Organisation For ResearchCentre Hospitalier Universitaire VaudoisExchange CommissionEuropean CommissionAmerican Joint Committee On CancerCommittee For Medicinal Products HumanMedicinal ProductsHuman UseAmerican Joint CommitteeMerck ResearchEuropean OrganisationEuropean Thoracic Oncology PlatformSelected Important SafetyImportant Safety InformationFatal Immune Mediated AdverseWhich Can Present With Diabetic
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1) -October 13, 2023 at 07:46 am EDT - Vimarsana News

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1) -October 13, 2023 at 07:46 am EDT

Published: October 13, 2023

Opinion granted based on positive overall survival results from the Phase 3 KEYNOTE-859 trial If approved, a KEYTRUDA combination would become an option in the EU for the treatment of both...

Source: marketscreener.com
Related Topics:
United StatesMerck Co IncEuropean UnionStatement Of Merck Co IncExchange CommissionMerck Research LaboratoriesEuropean CommissionEuropean Medicines AgencyMedicinal ProductsHuman UseCombined Positive ScoreMarjorie GreenMerck ResearchSelected Important SafetyImportant Safety InformationFatal Immune Mediated AdverseWhich Can Present With DiabeticNervous SystemConnective TissuePatients With MultipleNeck Squamous CellBacillus Calmette Guerin UnresponsiveMismatch Repair DeficientMismatch Repair Deficient ColorectalLooking Statement
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1) - Vimarsana News

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)

Published: October 13, 2023

RAHWAY, N.J.--(BUSINESS WIRE)--Oct 13, 2023--

Source: eagletribune.com
Related Topics:
United StatesPeter DannenbaumJulie CunninghamDamini ChokshiMichael McardleEuropean CommissionMerck Co IncStatement Of Merck Co IncEuropean UnionMerck Research LaboratoriesExchange CommissionEuropean Medicines AgencyMedicinal ProductsHuman UseCombined Positive ScoreMarjorie GreenMerck ResearchSelected Important SafetyImportant Safety InformationFatal Immune Mediated AdverseWhich Can Present With DiabeticNervous SystemConnective TissuePatients With MultipleNeck Squamous Cell
Turmalina Discovers High-Grade Gold Vein System Including 17.9 g/t Au Over 1.18 m - Vimarsana News

Turmalina Discovers High-Grade Gold Vein System Including 17.9 g/t Au Over 1.18 m

Published: October 10, 2023

VANCOUVER, British Columbia, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Turmalina Metals Corp. (“Turmalina”, or the “Company”; TBX-TSXV, TBXXF-OTCQX, 3RI...

Source: businessinsider.com
Related Topics:
United StatesSan FranciscoBritish ColumbiaUnited KingdomVeta AmarillaVilla NuevaRohan WolfeChico AzevedoVeta AlumbreraVeta RicaJames RogersCompany Stock Option PlanNational InstrumentCompany NewsBehalf Of The CompanyTurmalina Metals CorpSan JuanAustral GoldRica SurfaceVeta Rica SurfaceChief Executive OfficerCasposo MineEthan BrecciaTres MagosTurmalina Metals
Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease - Vimarsana News

Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease

Published: October 10, 2023

First Phase 3 survival data from KEYNOTE-A39/EV-302 support potential benefit of combination approach in previously untreated locally advanced or metastatic urothelial cancer; data are selected for...

Source: marketscreener.com
Related Topics:
United StatesSeagen PadcevSeagen IncEuropean Society For Medical OncologyAgensys IncMerck Research LaboratoriesMerck Co IncExchange CommissionStatement Of Merck Co IncEuropean SocietyMedical OncologyMarjorie GreenMerck ResearchOncology Investor EventProffered PaperBacillus Calmette Guerin UnresponsiveMismatch Repair Deficient ColorectalSelected Important SafetyImportant Safety InformationFatal Immune Mediated AdverseWhich Can Present With DiabeticNervous SystemConnective TissuePatients With MultipleNeck Squamous Cell